Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Amgen, Inc
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A study to evaluate the safety of panitumumab and children with solid tumours
To evaluate the safety and pharmacokinetics (PK) of up to 3 different dose schedules of panitumumab in pediatric subjects with solid tumors.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
An international research study to find out more about darbepoetin alfa in people with Myelodysplastic Syndrome (MDS) and anaemia. This study will see if darbepoetin alfa increases your haemoglobin levels and whether it causes any side effects. To do this, darbepoetin alfa will be compared to placebo. The placebo will look like the darbepoetin alfa but it will not contain any active ingredients. Taking placebo is the same as not taking any medication for your anaemia. Es un estudio de investigación internacional para averiguar más acerca de darbepoetin alfa en personas con síndrome mielodisplásico (SMD) y la anemia. Este estudio quiere ver si darbepoetin alfa aumenta sus niveles de hemoglobina y si causa efectos secundarios. Para ello, darbepoetina alfa se compara con un placebo. El placebo se parecerá a darbepoetina alfa, pero no contiene ningún prinicpio activo. Tomar placebo es lo mismo que no tomar ningún medicamento para tratar su anemia
To assess the superiority of darbepoetin alfa treatment compared with placebo on the proportion of subjects achieving International Working Group (IWG) erythroid response during the 24-week double-bli...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
The primary objective of this study is to evaluate the safety of romiplostim in adult thrombocytopenic subjects with ITP.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A Randomized, Double-Blind, Trial of AMG 745 or Placebo for the Treatment of Cachexia in Subjects with Non-Small Cell Lung Cancer
To evaluate the effect of AMG 745 on strength in subjects with cachexia due to NSCLC and to evaluate the safety and tolerability profile of AMG 745 in this patient population.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
An international study to Compare the Efficacy and Safety of Romosozumab With Placebo in Men With Osteoporosis
To evaluate the effect of treatment with romosozumab for 12 months compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual energy x ray absorptio...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
For the 12-month double-blind placebo-controlled study period: To assess the effect of romosozumab treatment for 12 months compared with placebo on the subject incidence of new vertebral fracture ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A Study of the Effects of AMG 334 to Prevent Migraine Headaches Estudio sobre la Eficacia de AMG 334 en Prevenir Migrañas
To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly migraine days, in subjects with episodic migraine Evaluar el efecto de AMG 334 en comparación con pla...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
The trial is designed to determine the safety and efficacy of ABP 501 compared with Adalimumab in subjects with moderate to severe plaque psorasis
The primary objective for this study is to evaluate the efficacy of ABP 501 in subjects with moderate to severe plaque psoriasis, as measured by the PASI percent improvement from baseline, compared wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A study assessing if long-term use of evolocumab will be safe, well tolerated, and whether it causes any side effects
To describe the safety and tolerability of long-term administration of evolocumab.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A Study to Test the Effect and Safety of Brodalumab Compared With Placebo and Ustekinumab and the Results of Changing Strength or Frequency of Brodalumab in People with Moderate to Severe Plaque Psoriasis: AMAGINE-3 Μια μελέτη για την εκτίμηση της αποτελεσματικότητας και της ασφάλειας με brodalumab έναντι εικονικού φαρμάκου και ustekinumab και τα αποτελέσματα and the Results of Changing Strength or Frequency of Brodalumab σε ασθενείς με μέτρια έως σοβαρή ψωρίαση κατά πλάκας: AMAGINE-3
Primary Placebo-family Objectives Compared with placebo: • To evaluate the efficacy of brodalumab (210 mg every 2 weeks [Q2W]; and 140 mg Q2W) in subjects with moderate to severe plaque psoriasis, ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant